| Outcome Measures: |
Primary: Change of bone density, Change from screening bone density of lumbar spine 1-4, neck of femur and whole femur at 48 weeks, Screening, 48 weeks|Change of CTX(C-terminal telopeptide of type I collagen), Change from baseline bone marker CTX(C-terminal telopeptide of type I collagen) at 12 weeks and 48 weeks., Baseline, 12 weeks, 48 weeks|Change of P1NP(Procollagen type 1 Aminoterminal Propeptide), Change from baseline bone marker P1NP(Procollagen type 1 Aminoterminal Propeptide) at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of 25OHD(25 Hydroxyvitamin D), Change from baseline bone metabolism indicator 25OHD(25 Hydroxyvitamin D) at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of PTH(Parathyroid Hormone) Intact, Change from baseline bone metabolism indicator PTH(Parathyroid Hormone) Intact at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of FGF23 (Fibroblast growth factor 23), Change from baseline bone metabolism indicator FGF23(Fibroblast growth factor 23) at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of 24 hour urine calcium, Change from baseline bone metabolism indicator 24 hour urine calcium at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of 24 hour urine phosphate, Change from baseline bone metabolism indicator 24 hour urine phosphate at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of 24 hour urine creatinine, Change from baseline bone metabolism indicator 24 hour urine creatinine at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks | Secondary: Change of HbA1C, Change from baseline HbA1C at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of FBS(Fasting Blood Sugar), Change from baseline FBS(Fasting Blood Sugar) at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of insulin, Change from baseline insulin at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of c-peptide, Change from baseline c-peptide at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of AGE(Advanced Glycation End Products), Change from baseline AGE(Advanced Glycation End Products) at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Change of CGM(Continuous Glucose Monitoring), Change from baseline CGM(Continuous Glucose Monitoring) at 12 weeks and 48 weeks, Baseline, 12 weeks, 48 weeks|Adverse events, Adverse events, 12 weeks, 24 weeks, 36 weeks, 48 weeks
|
| Locations: |
GangNeung Asan Hospital, Gangneung, Gangwondo, 25440, Korea, Republic of|Inha University Hospital, Incheon, 22332, Korea, Republic of|Kyung Hee University Hospital, Seoul, 02447, Korea, Republic of|Soon Chun Hyang University Hospital Seoul, Seoul, 04401, Korea, Republic of|Konkuk University Medical Center, Seoul, 05030, Korea, Republic of|Kyung Hee University Hospital at Gangdong, Seoul, 05278, Korea, Republic of|The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, 07345, Korea, Republic of
|
